About Lipella
Lipella is a company based in Pittsburgh (United States) founded in 2005. Lipella has raised $3.37 million across 17 funding rounds from investors including HHS and Military Health. The company has 7 employees as of December 31, 2024. Lipella offers products and services including LP-10, LP-310, LP-410, and LP-50. Lipella operates in a competitive market with competitors including TheraVida, Esprit Pharma, Regenfro Co, Kissei Pharmaceutical and Acerus Pharma, among others.
- Headquarter Pittsburgh, United States
- Employees 7 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lipella Pharmaceuticals Inc.
-
Annual Revenue
$536.36 K (USD)19.29as on Dec 31, 2024
-
Net Profit
-$5.02 M (USD)-8.6as on Dec 31, 2024
-
EBITDA
-$5.08 M (USD)-7.03as on Dec 31, 2024
-
Total Equity Funding
$3.37 M (USD)
in 17 rounds
-
Latest Funding Round
$3.79 M (USD), Post-IPO
Mar 04, 2025
-
Investors
HHS
& 1 more
-
Employee Count
7
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lipella
Lipella is a publicly listed company on the OTC with ticker symbol LIPO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lipella
Lipella offers a comprehensive portfolio of products and services, including LP-10, LP-310, LP-410, and LP-50.
Drug targeting bladder inflammation after radiation, based on clinical trial results.
Therapy for chronic oral inflammation with positive Phase 2a trial outcomes.
Drug for managing oral complications in transplant patients.
Potential therapy for bladder cancer using liposomal delivery technology.
People of Lipella
Unlock access to complete
Funding Insights of Lipella
Lipella has successfully raised a total of $3.37M across 17 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3.79 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lipella
Lipella has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Lipella
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lipella
Investment portfolio details for Lipella
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lipella
Detailed financials for Lipella
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lipella Comparisons
Peer comparison for Lipella
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lipella
Lipella operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TheraVida, Esprit Pharma, Regenfro Co, Kissei Pharmaceutical and Acerus Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Clinical stage biopharma company developing drugs for urology and central nervous system disorders
|
|
| Locked | Locked | Locked |
Develop drugs for genitourinary (GU) disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat renal diseases
|
|
| Locked | Locked | Locked |
Therapies for renal diseases and urology-related anemia are developed.
|
|
| Locked | Locked | Locked |
Develops pharmaceuticals for urology, hormone replacement therapy, and female sexual dysfunction treatments.
|
Detailed competitors of Lipella
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lipella
Complete news archive for Lipella
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lipella
Lipella was founded in 2005.
Lipella is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Lipella is a funded company, having raised a total of $3.37M across 17 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Lipella is 7.
Annual revenue of Lipella is $536.36K as on Dec 31, 2024.
Lipella was founded in 2005 in Pittsburgh, United States, within the biotechnology sector. Lipid-based therapies for bladder conditions are developed, focusing on intravesical delivery through urethral catheterization. Conditions addressed include interstitial cystitis, overactive bladder, and superficial bladder cancer. Formulations of multilamellar sphingomyelin liposomes are employed, binding to the bladder wall to establish a lipid barrier that supports tissue repair and shields against urinary irritants.
Lipella's top competitors include Kissei Pharmaceutical, Regenfro Co and Esprit Pharma.
Lipella offers LP-10, LP-310, LP-410, and LP-50.
Yes, Lipella is publicly traded on OTC under the ticker symbol LIPO.
Lipella has 2 investors. Key investors include HHS, and Military Health.
The ticker symbol of Lipella is LIPO on OTC.